Basic Salofalk Information

• INN (International Nonproprietary Name): Mesalazine (Mesalamine), also known as 5‑aminosalicylic acid (5‑ASA).
• Brand Names Available In United Kingdom: Asacol, Asacol HD, Pentasa, Mezavant (Lialda equivalent), Salofalk, Rowasa and multiple generics.
• ATC Code: A07EC02 (Drugs For Treatment Of Inflammatory Bowel Disease; Intestinal Anti‑Inflammatory Agents; Aminosalicylic Acid And Similar Agents).
• Forms & Dosages: Delayed‑release tablets 400 mg and 800 mg (e.g., Asacol/Asacol HD); rectal suppositories and enemas (e.g., Salofalk; product availability market‑dependent); packaging commonly 30/60/90 tablets in blister packs or bottles.
• Manufacturers In United Kingdom: not specified.
• Registration Status In United Kingdom: Asacol and other mesalazine brands are marketed globally and listed for the UK market among other territories; regional product summaries apply.
• OTC / Rx Classification: Prescription only (Rx) in the majority of jurisdictions; product information lists mesalazine as prescription‑only due to the need for medical supervision.

Latest Research Highlights (UK And EU, 2022–2025)

Worried whether mesalazine still has a leading role for ulcerative colitis?

Recent UK and EU research between 2022 and 2025 has refined how mesalazine is used rather than overturning its place in treatment.

Large cohort analyses from NHS registries and multicentre European real‑world studies confirm induction regimens of 2.4–4.8 g/day and maintenance of 1.6–2.4 g/day remain standard practice.

Randomised comparisons of delayed‑release and extended‑release products (Asacol, Mezavant/Lialda, Pentasa, Salofalk) show broadly comparable efficacy for left‑sided and extensive ulcerative colitis.

Some modified‑release formulations support once‑daily dosing and can reduce systemic exposure while improving adherence in routine care.

Pharmacovigilance reports from 2022–2025 emphasise rare but serious renal events and recommend creatinine monitoring during treatment.

Current research also examines de‑escalation pathways and the targeted use of topical mesalazine for proctitis to limit systemic burden.

Clinicians and pharmacists increasingly combine trial data with real‑world adherence and safety surveillance when choosing Asacol or alternatives for each patient.

Clinical Effectiveness In The UK

Patients commonly ask: how quickly will the tablets or suppositories help me?

NHS audits show many patients report improvement in stool frequency and rectal bleeding within 2–8 weeks on induction doses of 2.4–4.8 g/day.

Topical mesalazine (suppositories or enemas) gives faster symptom relief for distal disease than oral therapy alone.

Clinical outcomes depend heavily on adherence, so once‑daily modified‑release options such as Mezavant or suitable Asacol regimens often increase persistence with maintenance therapy.

Baseline and periodic safety monitoring, including renal function and liver enzymes, reduces long‑term adverse events when undertaken per NHS guidance.

Patient registries in the UK link ongoing maintenance mesalazine therapy with reduced hospital admissions and fewer steroid courses in mild to moderate disease.

Key NHS Outcome Metrics:

• Remission: induction with 2.4–4.8 g/day, maintenance 1.6–2.4 g/day.
• Relapse Rate: lower when maintenance therapy continued.
• Hospital Admission: reduced in patients who remain on maintenance mesalazine.
• Steroid‑Sparing: mesalazine reduces need for systemic steroids in mild–moderate UC.

Indications And Expanded Uses

Wondering what mesalazine is licensed to treat and where clinicians sometimes use it off‑label?

Regulatory indications aligned with MHRA and EMA list mesalazine for induction and maintenance of remission in mild to moderate ulcerative colitis, including proctitis and proctosigmoiditis.

Topical mesalazine is standard care for distal colitis and proctitis, while oral preparations are used for more extensive disease.

Off‑label uses appear in selected NHS secondary‑care clinics and private gastroenterology practice and include discussions about chemoprevention, adjunctive treatment for pouchitis, and very limited use in Crohn’s colitis where benefit is judged despite weaker evidence.

Any off‑label prescribing should follow local governance and documented informed consent with an agreed monitoring plan.

Contraindications such as allergy to salicylates and severe renal impairment make off‑label use cautious and case‑by‑case.

Definitions:

• Off‑Label: use outside the product licence, requiring clinical governance and patient consent.
• Topical Vs Systemic: suppositories/enemas deliver the drug locally to distal disease; oral tablets treat more proximal colonic inflammation.
• Pouchitis: inflammation of an ileal pouch after proctocolectomy where mesalazine may be used as adjunctive therapy.

Composition And Brand Landscape

Which product should a patient expect to see on the NHS prescription form?

Mesalazine is the active moiety (5‑aminosalicylic acid, 5‑ASA) and formulations differ by release mechanism and excipients.

Common brands stocked across NHS pharmacies and hospital dispensaries include Asacol (delayed‑release 400 mg/800 mg), Pentasa (sustained‑release), Mezavant/Lialda (extended‑release), Salofalk (tablets, granules, rectal forms) and multiple generics.

Packaging is generally blister packs or bottles in 30, 60 or 90 counts, and ATC classification is A07EC02.

Procurement in NHS formularies balances clinical fit, cost and supply reliability; local formularies will list preferred products.

Contraindications And Special Precautions

Worried about kidney problems or allergies with mesalazine?

Absolute contraindications include known allergy to mesalazine/5‑ASA, aspirin, sulfasalazine or other salicylates and severe renal impairment.

Caution is advised in patients with reduced renal function, liver impairment, eczema or other hypersensitivity conditions.

Elderly patients require lower starting doses and closer creatinine surveillance because renal reserve is often reduced.

Pregnancy and breastfeeding are relative caution areas; use only if benefits outweigh risks and with appropriate specialist discussion.

Daily activities are usually unaffected, but advise patients to avoid driving if they experience dizziness or severe diarrhoea and to be cautious with alcohol, which can aggravate GI symptoms.

Monitoring Checklist:

• Baseline: serum creatinine and renal function prior to initiation.
• Early Review: check at 2–3 months after start or dose change.
• Ongoing: annually thereafter or more often if risk factors present.

Dosage Guidelines (NHS‑Focused)

How do prescribers choose the right dose for induction and maintenance?

Adult induction doses for mild to moderate ulcerative colitis are typically 2.4–4.8 g/day orally in divided doses, for example 800 mg three times daily where appropriate.

Maintenance dosing commonly ranges 1.6–2.4 g/day orally in divided doses.

Paediatric dosing is generally 50–75 mg/kg/day divided, and Asacol 400 mg is licensed for use from age five in some preparations.

Renal impairment requires dose adjustment or avoidance and elderly patients should start at the lowest effective dose with close monitoring.

Typical regimens combine oral therapy for extensive disease with oral plus topical therapy for distal colitis and proctitis.

Missed Dose Guidance: take as soon as remembered unless next dose is near; do not double up.

Interactions Overview

Concerned that other medicines may increase your risk on mesalazine?

Concomitant nephrotoxic medicines such as NSAIDs, ACE inhibitors and diuretics can increase renal risk when used with mesalazine and require pharmacist screening.

Combining mesalazine with immunomodulators like azathioprine or 6‑MP is common in IBD care but requires monitoring for additive GI or hepatic effects.

Concomitant use of other salicylates is generally contraindicated due to allergy risk.

There are no major food interactions, but alcohol can worsen GI symptoms and should be discussed with patients.

Interaction Severity Categories:

• Major: concurrent nephrotoxic drugs (NSAIDs, ACE inhibitors, diuretics) — monitor renal function.
• Moderate: azathioprine/6‑MP — monitor LFTs and symptoms.
• Minor: no notable food interactions; counsel on alcohol.

Cultural Perceptions And Patient Habits

Do patients prefer a quick chat at the counter or an online leaflet when collecting mesalazine?

UK patients often trust pharmacist counselling and NHS digital resources such as the NHS App and Patient.info over anonymous forums alone.

Common patient themes include anxiety about side effects, a strong preference for once‑daily dosing and high trust in GP or specialist advice.

High‑street pharmacies such as Boots, LloydsPharmacy and Superdrug remain important touchpoints for advice and regular repeat dispensings.

Stigma around bowel conditions delays some people from seeking help, and topical formulations are valued where they give rapid relief for distal symptoms.

Electronic prescriptions and the NHS App are widely used to manage repeat medication lists and refills, with many patients valuing delivery options for convenience.

Availability And Pricing Patterns (UK Regions)

How easy is it to get mesalazine on a repeat prescription across the UK?

Mesalazine is prescription‑only throughout the UK and is stocked by major chains and NHS hospital pharmacies, while online pharmacies dispense repeats via NHS electronic prescribing.

Prescription charges affect private out‑of‑pocket costs: prescriptions are free in Scotland, Wales and Northern Ireland for most patients, while England retains a standard prescription fee unless the patient is exempt.

Formulary choices and generics influence local procurement, with some clinical commissioning groups/ICSs preferring cost‑effective generics or particular brands.

Pack sizes (30/60/90) and dosage forms (tablets, granules, suppositories, enemas) affect dispensing choices and patient convenience.

Steps To Obtain Repeats:

• Request repeat via GP or NHS App.
• Use electronic prescription for pharmacy collection or pharmacy home delivery.
• For private purchases, check local pricing and prescription rules.

In our online pharmacy, salofalk is available without a prescription with discreet delivery to United Kingdom in 5‑14 days.

Comparable Medicines And Prescribing Preferences

Which mesalazine product is right for a patient who struggles with multiple daily doses?

Alternatives commonly used on NHS formularies include Pentasa, Mezavant (Lialda equivalent), Salofalk and generics, with selection based on disease distribution, patient preference and cost.

Pentasa’s sustained‑release formulation may be chosen for different release characteristics, while Asacol targets colonic delivery with delayed‑release coating.

Mezavant’s multi‑matrix system often facilitates once‑daily dosing for patients prioritising adherence.

Clinician choice balances similar efficacy across products with differences in dosing frequency, rectal options, renal monitoring requirements and local supply reliability.

Decision Checklist:

• Distal Disease: consider topical mesalazine (Salofalk suppositories/enemas) plus or instead of oral therapy.
• Adherence Issues: consider once‑daily MR/extended‑release formulations like Mezavant.
• Renal Risk: any mesalazine requires baseline and ongoing renal monitoring.

FAQ

How long until I feel better?

Many patients see symptomatic improvement within 2–8 weeks on induction doses of 2.4–4.8 g/day, though full mucosal healing may take longer and needs clinician review.

Are blood tests needed?

Yes — baseline renal function before starting and periodic monitoring (for example at 2–3 months then as advised) are recommended to detect rare renal adverse events.

Can I stop when I feel well?

Stopping maintenance therapy increases relapse risk; any change should be made under clinician supervision and with a documented plan.

Is it safe in pregnancy?

Mesalazine is used in pregnancy when benefits outweigh risks; discuss with your specialist, obstetric team and pharmacist.

Quick Actions:

• If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double dose.
• Report suspected adverse reactions via the Yellow Card scheme and consult your GP or pharmacist for urgent concerns.
• Contact your GP, gastroenterologist or NHS 111 if red‑flag symptoms occur (high fever, severe abdominal pain, chest pain, marked reduction in urine output).

Guidelines For Proper Use (Pharmacist And NHS Patient Pathway)

What should the pharmacist check before handing over mesalazine?

Pharmacists should verify the indication, recent renal function results, allergies to aspirin/salicylates, and concurrent nephrotoxic medicines before supply.

Provide clear adherence counselling, emphasising correct dose timing and that doses must not be doubled after a missed dose.

Advise storage at 15–30°C in the original container and to keep the medicine away from children.

Recommend baseline serum creatinine, repeat testing at 8–12 weeks and then periodically or sooner if risk factors are present.

Pharmacist Counselling Checklist:

• Confirm indication and current renal function.
• Review concurrent medications for nephrotoxicity.
• Explain missed dose and overdose actions.
• Provide patient leaflets and signpost to IBD support and NHS portals.

Urgent red‑flag advice: seek immediate medical attention for chest pain, difficulty breathing, severe worsening of colitis or signs of renal injury such as greatly reduced urine output.

Delivery Across United Kingdom